No se ha completado ningn ensayo clnico de fase III en humanos hasta la fecha la mayora de los datos provienen de modelos animales
[DOI] [PMC free article] [PubMed] [Google Scholar] 22.Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., Egan J.M
Managing Energy Successfully on Semaglutide Fatigue on semaglutide is real but usually manageable and temporary
We also wish to thank Peter Ravn (MedImmune Ltd, Cambridge, UK) for intellectual input into GLP-1 analogue peptide stabilization, Bojana Popovic and Daniel Cannon (MedImmune Ltd, Cambridge, UK) for generating and analysing the peptide homology model, Adrian Podmore (MedImmune Ltd, Cambridge, UK) for conducting the aggregation and stability testing, Richard Kay (LGC, Fordham, UK) for conducting the mass spectrometry metabolites identification work, Marcella Petrone and John Hood (MedImmune Ltd, Cambridge, UK) for performing PK-PD simulations and analysis as well as Christopher Rhodes (MedImmune LLC, Gaithersburg, MD, USA) for his critical review of this manuscript
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
